| 1. Executive Summary |
| 2. Global Anti-Infective Market Introduction |
| 2.1. Global Anti-Infective Market – Taxonomy |
| 2.2. Global Anti-Infective Market –Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Indication |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Region |
| 3. Global Anti-Infective Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Anti-Infective Market Dynamic Factors – Impact Analysis |
| 3.6. Global Anti-Infective Market – Competition Landscape |
| 4. Global Anti-Infective Market Analysis,2017-2021 and Forecast, 2022-2028 |
| 4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Anti-Infective Market, By Product Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1. Antibacterials |
| 5.1.1. Cephalosporins |
| 5.1.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Penicillin |
| 5.1.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Fluoroquinolones |
| 5.1.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.1.4. Macrolides |
| 5.1.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.4.3. Market Opportunity Analysis |
| 5.1.5. Carbapenems |
| 5.1.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.5.3. Market Opportunity Analysis |
| 5.1.6. Others |
| 5.1.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.6.3. Market Opportunity Analysis |
| 5.2. Antifungals |
| 5.2.1. Azoles |
| 5.2.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Echinocandins |
| 5.2.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Polyenes |
| 5.2.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.2.4. Others |
| 5.2.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.4.3. Market Opportunity Analysis |
| 5.3. Antivirals |
| 5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Anti-Infective Market Forecast, By Indication, 2017-2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
| 6.1. Pneumonia |
| 6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Sepsis |
| 6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Tuberculosis |
| 6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Dermatophytosis |
| 6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Aspergillosis |
| 6.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Candidiasis |
| 6.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Hepatitis Virus Infection |
| 6.8.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. HIV Infection |
| 6.9.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 6.10. Respiratory Virus Infection |
| 6.10.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.10.3. Market Opportunity Analysis |
| 6.11. Others |
| 6.11.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.11.3. Market Opportunity Analysis |
| 7. Global Anti-Infective Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Specialty Pharmacy |
| 7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. E-commerce |
| 7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Anti-Infective Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Region, 2022-2028 |
| 9. North America Anti-Infective MarketAnalysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.1. By Product Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Antibacterials |
| 9.1.1.1. Cephalosporins |
| 9.1.1.2. Penicillin |
| 9.1.1.3. Fluoroquinolones |
| 9.1.1.4. Macrolides |
| 9.1.1.5. Carbapenems |
| 9.1.1.6. Others |
| 9.1.2. Antifungals |
| 9.1.2.1. Azoles |
| 9.1.2.2. Echinocandins |
| 9.1.2.3. Polyenes |
| 9.1.2.4. Others |
| 9.1.3. Antivirals |
| 9.2. Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Pneumonia |
| 9.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 9.2.3. Sepsis |
| 9.2.4. Tuberculosis |
| 9.2.5. Dermatophytosis |
| 9.2.6. Aspergillosis |
| 9.2.7. Candidiasis |
| 9.2.8. Hepatitis Virus Infection |
| 9.2.9. HIV Infection |
| 9.2.10. Respiratory Virus Infection |
| 9.2.11. Others |
| 9.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Hospital Pharmacy |
| 9.3.2. Retail Pharmacy |
| 9.3.3. Specialty Pharmacy |
| 9.3.4. E-commerce |
| 9.3.5. Others |
| 9.4. Country Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2022-2028 |
| 9.6. North America Anti-Infective Market Dynamics – Trends |
| 10. Europe Anti-Infective Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.1. By Product Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Antibacterials |
| 10.1.1.1. Cephalosporins |
| 10.1.1.2. Penicillin |
| 10.1.1.3. Fluoroquinolones |
| 10.1.1.4. Macrolides |
| 10.1.1.5. Carbapenems |
| 10.1.1.6. Others |
| 10.1.2. Antifungals |
| 10.1.2.1. Azoles |
| 10.1.2.2. Echinocandins |
| 10.1.2.3. Polyenes |
| 10.1.2.4. Others |
| 10.1.3. Antivirals |
| 10.2. Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Pneumonia |
| 10.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 10.2.3. Sepsis |
| 10.2.4. Tuberculosis |
| 10.2.5. Dermatophytosis |
| 10.2.6. Aspergillosis |
| 10.2.7. Candidiasis |
| 10.2.8. Hepatitis Virus Infection |
| 10.2.9. HIV Infection |
| 10.2.10. Respiratory Virus Infection |
| 10.2.11. Others |
| 10.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospital Pharmacy |
| 10.3.2. Retail Pharmacy |
| 10.3.3. Specialty Pharmacy |
| 10.3.4. E-commerce |
| 10.3.5. Others |
| 10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2022-2028 |
| 10.6. Europe Anti-Infective Market Dynamics – Trends |
| 11. Asia-Pacific Anti-Infective Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 11.1. By Product Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Antibacterials |
| 11.1.1.1. Cephalosporins |
| 11.1.1.2. Penicillin |
| 11.1.1.3. Fluoroquinolones |
| 11.1.1.4. Macrolides |
| 11.1.1.5. Carbapenems |
| 11.1.1.6. Others |
| 11.1.2. Antifungals |
| 11.1.2.1. Azoles |
| 11.1.2.2. Echinocandins |
| 11.1.2.3. Polyenes |
| 11.1.2.4. Others |
| 11.1.3. Antivirals |
| 11.2. Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Pneumonia |
| 11.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 11.2.3. Sepsis |
| 11.2.4. Tuberculosis |
| 11.2.5. Dermatophytosis |
| 11.2.6. Aspergillosis |
| 11.2.7. Candidiasis |
| 11.2.8. Hepatitis Virus Infection |
| 11.2.9. HIV Infection |
| 11.2.10. Respiratory Virus Infection |
| 11.2.11. Others |
| 11.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospital Pharmacy |
| 11.3.2. Retail Pharmacy |
| 11.3.3. Specialty Pharmacy |
| 11.3.4. E-commerce |
| 11.3.5. Others |
| 11.4. Country Analysis2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2022-2028 |
| 11.6. Asia-Pacific Anti-Infective Market Dynamics – Trends |
| 12. Latin America Anti-Infective Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 12.1. By Product Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Antibacterials |
| 12.1.1.1. Cephalosporins |
| 12.1.1.2. Penicillin |
| 12.1.1.3. Fluoroquinolones |
| 12.1.1.4. Macrolides |
| 12.1.1.5. Carbapenems |
| 12.1.1.6. Others |
| 12.1.2. Antifungals |
| 12.1.2.1. Azoles |
| 12.1.2.2. Echinocandins |
| 12.1.2.3. Polyenes |
| 12.1.2.4. Others |
| 12.1.3. Antivirals |
| 12.2. Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Pneumonia |
| 12.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 12.2.3. Sepsis |
| 12.2.4. Tuberculosis |
| 12.2.5. Dermatophytosis |
| 12.2.6. Aspergillosis |
| 12.2.7. Candidiasis |
| 12.2.8. Hepatitis Virus Infection |
| 12.2.9. HIV Infection |
| 12.2.10. Respiratory Virus Infection |
| 12.2.11. Others |
| 12.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospital Pharmacy |
| 12.3.2. Retail Pharmacy |
| 12.3.3. Specialty Pharmacy |
| 12.3.4. E-commerce |
| 12.3.5. Others |
| 12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2022-2028 |
| 12.6. Latin America Anti-Infective Market Dynamics – Trends |
| 13. Middle East and Africa Anti-Infective Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 13.1. By Product Type Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Antibacterials |
| 13.1.1.1. Cephalosporins |
| 13.1.1.2. Penicillin |
| 13.1.1.3. Fluoroquinolones |
| 13.1.1.4. Macrolides |
| 13.1.1.5. Carbapenems |
| 13.1.1.6. Others |
| 13.1.2. Antifungals |
| 13.1.2.1. Azoles |
| 13.1.2.2. Echinocandins |
| 13.1.2.3. Polyenes |
| 13.1.2.4. Others |
| 13.1.3. Antivirals |
| 13.2. Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Pneumonia |
| 13.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA) |
| 13.2.3. Sepsis |
| 13.2.4. Tuberculosis |
| 13.2.5. Dermatophytosis |
| 13.2.6. Aspergillosis |
| 13.2.7. Candidiasis |
| 13.2.8. Hepatitis Virus Infection |
| 13.2.9. HIV Infection |
| 13.2.10. Respiratory Virus Infection |
| 13.2.11. Others |
| 13.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospital Pharmacy |
| 13.3.2. Retail Pharmacy |
| 13.3.3. Specialty Pharmacy |
| 13.3.4. E-commerce |
| 13.3.5. Others |
| 13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Anti-Infective Market – Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Country, 2022-2028 |
| 13.6. MEA Anti-Infective Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Gilead Sciences |
| 14.2.2. GlaxoSmithKline |
| 14.2.3. Merck & Co |
| 14.2.4. Johnson & Johnson |
| 14.2.5. Pfizer Inc. |
| 14.2.6. AbbVie |
| 14.2.7. Bayer AG |
| 14.2.8. Mylan N.V. |
| 14.2.9. Shionogi |
| 14.2.10. F. Hoffmann-La Roche Ltd |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Request Sample
Request Methodology
